Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

1998 • 2,374 citations

Hepatitis C Virus Type 1b (II) Infection in France and Italy

1995 • 490 citations

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C

1995 • 474 citations

Factors predictive of a beneficial response to therapy of hepatitis C

1997 • 339 citations

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C

1996 • 253 citations

Clinical Pharmacokinetics of Interferons

1990 • 245 citations

Quantification of the initial decline of serum hepatitis c virus RNA and response to interferon alfa

1998 • 171 citations

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C

1997 • 156 citations

Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable Drugs

2000 • 155 citations

Determination of Hepatitis C Virus Genotype by Direct Sequence Analysis of Products Generated with the Amplicor HCV Test

1999 • 133 citations

Adverse Effects and Drug Interactions of Clinical Importance with Antiviral Drugs

1994 • 65 citations

Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long‐term response in chronic hepatitis C

1997 • 37 citations

Viral kinetics can predict early response to alpha-interferon in chronic hepatitis C

1998 • 12 citations

Comparison of thrice weekly vs daily human leucocyte interferon‐α therapy for chronic hepatitis C

1999 • 10 citations

Cited By (0)

No citing papers found in database